Navigation Links
OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
Date:12/6/2007

phthalmic diseases, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts: Media:

Corporate: GendeLLindheim BioCom Partners

Steven D. Rubin Barbara Lindheim

305 575 6000 212 91
'/>"/>

SOURCE OPKO Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Keith Taft Named General Manager of UltraTape Industries
2. Summa Health Systems Akron City Hospital Named Leapfrog Top Hospital for 2007
3. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
4. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
5. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
6. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
7. New Director of Nursing Practice Named for Nurses Association
8. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
9. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
10. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
11. AIUM CEO named among most influential in radiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... TeamPraxis, Hawaii,s premier physician management service organization (MSO) that ... Hawaii physicians, capped off its inaugural year of selling ... with seven new large client signings, bringing the first-year ... , , These sales completed a very successful ...
... ... , ... 2009 -- Talyst , a leader in pharmacy automation systems, found June to be ... was awarded as one of "Washington,s 100 Best Companies to Work For 2009" by Seattle ...
... MEDai, Inc. and Gold Standard, Inc., two Elsevier companies, ... medication therapy management (MTM) system that enables health plans, benefit ... Program requirements for 2010 and beyond for their Medicare Part ... to reporting and outcomes measurement. MTM 360 ...
... ... last year, blue sky scrubs has added new products and features, updated their content and ... ... has released a new version of their website, http://www.blueskyscrubs.com . Some of the ...
... ... for their HEPA-CARE® Air Filtration Systems and Germicidal UV Modules from healthcare facilities ... ... 2009 -- Abatement Technologies®, Inc. sees strong demand for their HEPA-CARE® Air Filtration ...
... Jesse ... delighted to announce ONRAD,s new web based PACS Application Service Provider (ASP) model. , ... Riverside, CA (PRWEB) July 9, 2009 ... (ONRAD) is delighted to announce ONRAD,s new web based PACS Application Service Provider (ASP) model. ...
Cached Medicine News:Health News:TeamPraxis Finishes Strong First Year of National Sales 2Health News:TeamPraxis Finishes Strong First Year of National Sales 3Health News:TeamPraxis Finishes Strong First Year of National Sales 4Health News:TeamPraxis Finishes Strong First Year of National Sales 5Health News:Talyst Receives Multiple Honors for Workplace Excellence 2Health News:Talyst Receives Multiple Honors for Workplace Excellence 3Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 2Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 3Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 4Health News:Nursing Scrubs and Medical Scrubs Company blue sky scrubs Launches Enhanced Website 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 3Health News:ONRAD Announces New PACS Application Service Provider Model 2
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
(Date:10/17/2014)... 17, 2014  UBM Medica US announces that ... and other clinicians who treat patients with type ... effective use of insulin .  Nearly ... replacement therapy – daily injections of one or ... in the function of pancreatic beta cells. Insulin is ...
(Date:10/17/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... biopharmaceutical company in China , ... from the China Food and Drug Administration (the ... concentrate ("PCC") at its Shandong Taibang facility. The ... facility for Good Manufacturing Practices ("GMP") compliance in ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Incorporated,(Nasdaq: VPHM ) today announced that Michel de ... at the Acumen BioFin Rodman &,Renshaw 9th Annual Healthcare ... The conference is being held at the New York ... investors through, http://www.viropharma.com and available through November 20, ...
... Research,Associates, LLC announced today that it has ... Corporation (Amex: CVM ). The,full 56-page ... . CEL-SCI Corporation develops immune-based cancer ... is Multikine(R), a,next-generation, comprehensive immunotherapy that targets ...
Cached Medicine Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 3
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: